Fundraising Fox
/Companies
Sign in

Arthrosi

San Diego, US · Founded 2017 · 8 known investors

Find your way into Arthrosi

Sign up to see every warm intro you have to Arthrosi

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Arthrosi team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Arthrosi Therapeutics is a clinical-stage biopharmaceutical company developing treatments for gout, an inflammatory arthritis condition. Its lead molecule, AR882, is a urate-lowering agent aimed at reducing uric acid, tophi, and gout flares.

BiotechDigital HealthMedical Devices

Founders & leadership

Arthrosi was founded in 2017 by Litain Yeh and Shunqi Yan.

LYLitain Yeh
Litain YehCo-Founder & Chief Executive OfficerExecutive Officer, Director, Promoter at Arthrosi Therapeutics
SY
Shunqi YanCo-Founder & Chief Operating Officer
RO
Robert OrrNamed on SEC filing
YZ
Yiwei ZongNamed on SEC filing
JF
Jianfeng FangNamed on SEC filing

Board

ZM
Zhang MingyuanBoard director
CY
Chaohua YuanBoard director
XW
Xiaodong WangBoard director
HL
Hanxiong LiBoard director
TH
Thomas HuangBoard director
XX
Xin XieBoard director
JL
John LeamanBoard director

Investors · 8

Maxpro Ventureslisted by Maxpro VenturesTaipei

How we know: Maxpro Ventures's portfolio page · Not right? Tell us

Highlight CapitalreportedNanjin

How we know: funding news · fiercebiotech.com · Not right? Tell us

Also in the syndicate · 5

CR BiotechPrime Eight CapitalleadPrime Eight Capital LimitedleadReliantTechReliantTech Limited

Funding

SEC filings, press & company announcements

$285.9M disclosed across 9 rounds · 2018–2025

▶$60.9MraisedJun 2025 · 13 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Zhang MingyuanDirector
  • Chaohua YuanDirector
  • Xiaodong WangDirector
  • John LeamanDirector
  • Hanxiong LiDirector
  • Thomas HuangDirector
  • Xin XieDirector
  • Litain YehExecutive Officer, Director, Promoter
  • Shunqi YanExecutive Officer, Director, Promoter
Offering amount
$153.1M
Amount sold
$60.9M
First sale
Jun 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$7MraisedJan 2024 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Xin XieDirector
  • Chaohua YuanDirector
  • James McKayDirector
  • Xiaodong WangDirector
  • Hanxiong LiDirector
  • Shunqi YanExecutive Officer, Director, Promoter
  • Litain YehExecutive Officer, Director, Promoter
  • Xiaojia CaiDirector
Offering amount
$75M
Amount sold
$7M
First sale
Sep 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$15MraisedMar 2023 · 2 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Yiwei ZongDirector
  • Xiaojia CaiDirector
  • Litain YehExecutive Officer, Director, Promoter
  • Shunqi YanExecutive Officer, Director, Promoter
  • Xin XieDirector
  • Hanxiong LiDirector
  • James McKayDirector
Offering amount
$20M
Amount sold
$15M
First sale
Feb 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$220KraisedNov 2021 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Litain YehExecutive Officer, Director, Promoter
  • Shunqi YanExecutive Officer, Director, Promoter
  • Xie XinDirector
  • Li HanxiongDirector
  • Cynthia CaiDirector
  • James MackayDirector
  • Yiwei ZhongDirector
Offering amount
$220K
Amount sold
$220K
First sale
Aug 2021
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$26MraisedNov 2021 · 2 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Hanxiong LiDirector
  • James MackayDirector
  • Cynthia CaiDirector
  • Xie XinDirector
  • Litain YehExecutive Officer, Director, Promoter
  • Shunqi YanExecutive Officer, Director, Promoter
  • Yiwei ZhongDirector
Offering amount
$30M
Amount sold
$26M
First sale
Aug 2021
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$8.5MraisedJun 2020 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Litain YehExecutive Officer, Director, Promoter
  • Shunqi YanExecutive Officer, Director, Promoter
  • Yiwei ZongDirector
  • Robert OrrExecutive Officer, Director, Promoter
  • Jianhua CaiDirector
Offering amount
$20M
Amount sold
$8.5M
First sale
May 2020
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$11MraisedJan 2019 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Yiwei ZongDirector
  • Litain YehExecutive Officer, Director, Promoter
  • Shunqi YanExecutive Officer, Director, Promoter
  • Robert OrrExecutive Officer, Director, Promoter
  • Jianhua CaiDirector
Offering amount
$11M
Amount sold
$11M
First sale
Oct 2018
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4.3MraisedJun 2018 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Robert OrrExecutive Officer, Director, Promoter
  • Shunqi YanExecutive Officer, Director, Promoter
  • Litain YehExecutive Officer, Director, Promoter
  • Yiwei ZongDirector
  • Jianfeng FangDirector
Offering amount
$4.3M
Amount sold
$4.3M
First sale
Jan 2018
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Arthrosi Secures $153M in Series E Fundingfinsmes.com · Oct 2025Arthrosi Therapeutics Raises $75M in Series D Fundingfinsmes.com · Jul 2023

Frequently asked questions

What does Arthrosi do?
Arthrosi Therapeutics is a clinical-stage biopharmaceutical company developing treatments for gout, an inflammatory arthritis condition. Its lead molecule, AR882, is a urate-lowering agent aimed at reducing uric acid, tophi, and gout flares.
Who founded Arthrosi?
Arthrosi was founded by Litain Yeh, Shunqi Yan in 2017.
Who are Arthrosi's investors?
Arthrosi's investors include HM Venture Partners, Maxpro Ventures, Highlight Capital.
How much funding has Arthrosi raised?
Arthrosi has disclosed $285.9M raised across 9 rounds.
Where is Arthrosi headquartered?
Arthrosi is headquartered in San Diego, US.